Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) mutations are the most frequent driver mutations in non-small-cell lung cancer (NSCLC).
• EGFR-tyrosine kinase inhibitors (TKIs) have significantly improved treatment outcomes for patients with EGFR-sensitive mutations.
• Despite advances, primary and secondary drug resistance mutations remain a significant clinical challenge in EGFR-mutated NSCLC.

Purpose of the Study:

• To review the current challenges in targeted therapy for EGFR mutation-positive NSCLC.
• To explore emerging coping strategies and novel drug targets to overcome resistance.
• To provide an overview of the evolving landscape of NSCLC treatment resistance.

Main Methods:

• Literature review of recent research on EGFR mutations in NSCLC.
• Analysis of drug resistance mechanisms and emerging therapeutic targets.
• Synthesis of current strategies to combat nonclassical drug resistance.

Main Results:

• Targeted therapies offer improved prognosis but are limited by resistance.
• Continuous discovery of new drugs and resistance targets is crucial.
• Advancements are being made to overcome NSCLC drug resistance.

Conclusions:

• EGFR-targeted therapy for NSCLC faces significant challenges due to drug resistance.
• Ongoing research into novel drugs and resistance mechanisms is vital.
• Developing effective strategies to overcome resistance is key to improving long-term patient outcomes.